Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Intra-Cellular Therapies, Inc. (ITCI)

54.09   0.87 (1.63%) 12-07 16:00
Open: 52.9 Pre. Close: 53.22
High: 54.98 Low: 52.9
Volume: 615,196 Market Cap: 5,123(M)

Technical analysis

as of: 2022-12-07 4:23:19 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 64.21     One year: 75
Support: Support1: 48.1    Support2: 43.85
Resistance: Resistance1: 54.97    Resistance2: 64.21
Pivot: 52.61
Moving Average: MA(5): 53.81     MA(20): 52.22
MA(100): 50.58     MA(250): 52.58
MACD: MACD(12,26): 1.3     Signal(9): 1.2
Stochastic oscillator: %K(14,3): 82.5     %D(3): 83.4
RSI: RSI(14): 59.7
52-week: High: 66  Low: 34.88
Average Vol(K): 3-Month: 691 (K)  10-Days: 453 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ITCI ] has closed below upper band by 21.5%. Bollinger Bands are 33.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 55.02 - 55.28 55.28 - 55.53
Low: 52.24 - 52.54 52.54 - 52.82
Close: 53.6 - 54.07 54.07 - 54.51

Company Description

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Headline News

Wed, 07 Dec 2022
Stock Market Extends Losses As Corporate Earnings Not Enough To Allay Investor Concerns - Investor's Business Daily

Fri, 02 Dec 2022
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Sells $2686500.00 in Stock - MarketBeat

Wed, 30 Nov 2022
Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year? - Nasdaq

Sat, 26 Nov 2022
Is Intra-Cellular Therapies (ITCI) Stock a Worthy Buy? - Yahoo Finance

Fri, 18 Nov 2022
Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe - Zacks Investment Research

Fri, 11 Nov 2022
Have Insiders Sold Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Recently? - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 95 (M)
Shares Float 88 (M)
% Held by Insiders 2.6 (%)
% Held by Institutions 94.4 (%)
Shares Short 4,060 (K)
Shares Short P.Month 4,080 (K)

Stock Financials

EPS -3.61
EPS Est Next Qtl -0.69
EPS Est This Year -2.34
EPS Est Next Year -2.81
Book Value (p.s.) 7.23
Profit Margin (%) -158.4
Operating Margin (%) -160.7
Return on Assets (ttm) -28.3
Return on Equity (ttm) -50.9
Qtrly Rev. Growth 223.6
Gross Profit (p.s.) -0.14
Sales Per Share 1.98
EBITDA (p.s.) -3.19
Qtrly Earnings Growth 0
Operating Cash Flow -304 (M)
Levered Free Cash Flow -196 (M)

Stock Valuations

PE Ratio -14.99
PEG Ratio -0.1
Price to Book value 7.47
Price to Sales 27.23
Price to Cash Flow -16.85

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.